CD274 and non-small cell lung carcinoma: Additionally, in previously untreated, PD-L1 positive advanced NSCLC, ivonescimab monotherapy resulted in significantly longer PFS compared to pembrolizumab (25), leading to its approval by the NMPA in April 2025 for first-line treatment of PD-L1 positive (TPS ≥1%) disease.